However, a comprehensive understanding of how the pro-survival Bcl-2 family members expression in CRC patients influences the clinical development of small molecule inhibitors targeting these proteins remains largely unexplored, particularly in the combination setting. This evidence concerns the gene BCL2 and colorectal carcinoma.